Johnson & Johnson's nasal spray for depression wins FDA panel backing
(Reuters) – An advisory panel to the U.S. Food and Drug Administration on Tuesday voted in favor of Johnson & Johnson’s experimental nasal spray, which has a compound similar to often-abused ketamine, bringing the drug closer to approval. FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California, U.S., January 24, 2017. REUTERS/Mike […]